Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DORYX MPC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus DORYX MPC.
DEMECLOCYCLINE HYDROCHLORIDE vs DORYX MPC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Doxycycline, a tetracycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the mRNA-ribosome complex.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
100 mg orally twice daily on day 1, then 100 mg once daily; alternatively, 200 mg orally once daily.
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 25–30 hours) or with hepatic dysfunction.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Renal (approximately 40% as unchanged drug via glomerular filtration), fecal/biliary (up to 30% as conjugated or inactive metabolites), remainder metabolized.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic